Certified Diabetes Educator Exam
The National Certification Board for Diabetes Educators (NCBDE) offers the Certification Examination for Diabetes Educators for certification purposes. Candidates must meet specific academic and work experience eligibility requirements before taking this test. After successfully becoming certified, candidates may use the title of Certified Diabetes Educator or the acronym CDE after their name as long as it is up to date.
Candidates will have four hours to finish 200 multiple-choice items on this computer-based assessment. Of these, 25 items are not scored; these are pre-trial items which may be used on future exams. Candidates will not know which items are scored and which are not.
Candidates may use a hand-held calculator. It has to run on a battery or by solar power, and it cannot have any ability to program information. Nothing else is allowed, and a pencil will be provided at the test location.
The content of the test is broken down as follows:
- 40 questions on assessment
- 120 questions on intervention
- 15 questions on program development and administration
The raw score (the number answered correctly) will be converted to a scaled score in the 0-99 range. The minimum passing scaled score is 70. After passing the exam, candidates will receive a certificate and wallet card.
Free CDE Practice Test Questions
1. Plasma glucose goals in pregnancy are
- <110 mg/dl preprandial and <130 mg/dl peak postprandial.
- <100 mg/dl preprandial and <120 mg/dl peak postprandial.
- <100 mg/dl preprandial and <130 mg/dl peak postprandial.
- <90 mg/dl preprandial and <120 mg/dl peak postprandial.
2. Which of the following are the current target A1c goals recommended for type 1 diabetes in children?
- 0-6 years old, 7.5-8.5%; 6-12 years old, <8%; and 13-19 years old, <7.5%
- 0-6 years old, <9%; 6-12 years old, <8%; and 13-19 years old, <7%
- 0-5 years old, 8.5-9.5%; 7-12 years old, 8-9%; and 13-19 years old, <7%
- none of the above
3. Would a woman using a rapid-acting insulin analog be required to switch to a different type of insulin after becoming pregnant?
- No, adequate studies have confirmed the safety of rapid-acting insulin during pregnancy.
- Yes, a change to short-acting insulin would be required because it has been used without associated problems for years.
- Yes, a change to short-acting and intermediate-acting insulin would be required.
- No, but the woman would be required to take short-acting insulin with it.
4. Which of the followings statements is not correct related to the use of Glucagon in diabetes management?
- Glucagon is a hormone secreted by the pancreas, which triggers the liver to release glucose stores into the bloodstream.
- Glucagon is normally administered to an individual with diabetes when they are unconscious in response to hypoglycemia.
- Individuals with depleted glycogen stores may not respond to a Glucagon injection.
- Glucagon must be administered through an intravenous injection.
5. The current American Diabetes Association (ADA) recommendation for protein restriction in patients with early-stage of nephropathy is
- 1.0-2.0 g/kg body weight/day.
- 1.5 g/kg body weight/day.
- 0.5 g/kg body weight/day.
- 0.8-1.0 g/kg body weight/day.
Answers & Explanations
1. C: This answer includes the ADA’s most recent recommendations for PG control in pregnancy. It is well established that the children born to women with diabetes have an increased risk of congenital malformations, macrosomia, and other medical issues. Maintaining PG as near to normal as possible during the pregnancy is indicated to reduce risk.
2. A: This is a listing of the ADA’s 2009 standards of medical care in diabetes for A1c goals in type 1 diabetes per age group.
3. A: The Key to FDA Use-In Pregnancy Rating system rates both rapid acting insulin lispro (Humalog) and aspart (Novolog) as category B. This category indicates that no evidence of risk to humans has been seen in what they term “adequate, well-controlled studies of pregnant women.” Physicians routinely prescribed short-acting and intermediate-acting insulin in pregnancy before studies validated the safety of rapid-acting insulin. However, short-acting and intermediate-acting insulin do not carry a rating. Of the combination insulins, only lispro protamine/insulin lispro (Humalog Mix 75/25) carries a rating of category B. Other combination insulins are either not rated or are rated category C. Category C means that risk cannot be ruled out. Lastly, the long-acting insulins glargine (Lantus) and detemir (Levemir) carry a rating of category C.
4. D: Glucagon in the form of a Glucagon Support Kit requires a prescription and is normally prescribed for individual experiencing hypoglycemia unawareness. Glucagon is available in powdered form and must be infused into liquid and then drawn back into the syringe prior to administration. Glucagon can be given as an intravenous, intramuscular, or subcutaneous injection. Unless an individual has depleted glycogen stores, the glucagon injection should bring them back to consciousness within 15 minutes. Individuals with depleted glycogen stores will require intravenous dextrose administration. It is always important to place the individual receiving glucagon on their side, because they may vomit in response to the glucagon injection and the rapid elevation in blood glucose.
5. D: The current position of the ADA for patients in an early stage of nephropathy is use of the current adult Recommended Dietary Allowance (RDA). Studies have shown a small reduction in the progression toward renal failure when protein intake is restricted to 0.8 g/kg body weight/day. However, a restriction from 0.8 to 1.0 g/kg body weight/day is restricted in relation to the amount of protein provided by a typical American diet.